Inhibition of airway proteases in cystic fibrosis lung disease

European Respiratory Journal

Volumn 32, Issue 3, 2008, Pages 783-795

  Griese, M ^a,c   Kappler, M ^a   Gaggar, A ^b   Hartl, D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antiproteases; Antitrypsin; Cystic fibrosis; Elastase; Lung disease; Proteases

Indexed keywords

[4 (4 BROMOPHENYLSULFONYLCARBAMOYL)BENZOYL]VALYLPROLINE N (2 METHYL 1 TRIFLUOROACETYLPROPYL)AMIDE; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; COLISTIN; ELAFIN; ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; MACROLIDE; MIDESTEINE; N [1 (1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL 2 [4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SIVELESTAT; SUPG 032; UNCLASSIFIED DRUG; ZEMAIRA; LEUKOCYTE ELASTASE; PROTEINASE INHIBITOR;

ANAPHYLAXIS; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNE SYSTEM; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFECTION; LUNG LAVAGE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; BRONCHUS; CYSTIC FIBROSIS; DRUG EFFECT; ENZYMOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA 1-ANTITRYPSIN; BRONCHI; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; HUMANS; LEUKOCYTE ELASTASE; PROTEASE INHIBITORS;

EID: 58149394958     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00146807     Document Type: Review

References (140)

1. Davis PB, Drumm M, Konstan M. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-1256.
2. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28: 331-346.
3. Gentzsch M, Choudhury A, Chang XB, Pagano RE, Riordan JR. Misassembled mutant ΔF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J Cell Sci 2007; 120: 447-455.
4. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. New Engl J Med 1995; 332: 848-854.
5. Konstan MW, Krenicky JE, Finney MR, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003; 306: 1086-1091.
6. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089.
7. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in cystic fibrosis patients. Am J Respir Crit Care Med 2004; 169: 719-725.
8. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 1356-1362.
9. 4 receptor antagonist) for the treatment of CF lung disease. Ped Pulm 2005; 40: Suppl. 28, 125-126.
10. Abbott J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes 2005; 24: 19.
11. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
12. Aurora P, Gustafsson P, Bush A, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004; 59: 1068-1073.
13. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23: 93-97.
14. Brand P, Meyer T, Häussermann S, et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 2005; 18: 45-54.
15. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-1204.
16. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002; 141: 811-817.
17. Prasad SA, Randall SD, Balfour-Lynn IM. Fifteen-count breathlessness score: an objective measure for children. Pediatr Pulmonol 2000; 30: 56-62.
18. Ramsey BW, Astley S, Aitken M, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151.
19. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004; 17: 57-71.
20. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007; 42: 729-735.
21. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 1471-1475.
22. Downey DG, Martin SL, Dempster M, et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007; 42: 216-220.
23. Doring G, Elborn JS, Johannesson M, et al. Clinical trials in cystic fibrosis. J Cyst Fibros 2007; 6: 85-99.
24. Bonfield TL. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
25. Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against Gram negative bacterial sepsis. Nat Med 1998; 4: 615-618.
26. Belaaouaj A. Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis. Microbes Infect 2002; 4: 1259-1264.
27. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
28. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5: 577-582.
29. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176: 231-241.
30. Urban CF, Reichard U, Brinkmann V, Zychlinsky A. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol 2006; 8: 668-676.
31. Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985; 132: 417-433.
32. Fujita J, Nelson NL, Daughton DM, et al. Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis 1990; 142: 57-62.
33. Birrer P, McElvaney N, Rüderberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
34. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 1986; 153: 902-909.
35. Suter S. Imbalance between polymorphonuclear leukocyte proteases and antiproteases in chronic pyogenic infections and its relation to the proteolysis of complement component C3. Complement 1986; 3: 1-24.
36. 1- Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 1993; 148: 1665-1670.
37. Döring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: 114-117.
38. Rees DD, Brain JD, Wohl ME, Humes JL, Mumford RA. Inhibition of neutrophil elastase in CF sputum by L-658,758. J Pharmacol Exp Ther 1997; 283: 1201-1206.
39. Janoff A. Mediators of tissue damage in human polymorphonuclear neutrophils. Ser Haematol 1970; 3: 96-130.
40. Janoff A. Human granulocyte elastase. Further delineation of its role in connective tissue damage. Am J Pathol 1972; 68: 579-592.
41. Janoff A. Neutrophil proteases in inflammation. Annu Rev Med 1972; 23: 177-190.
42. Janoff A. Proteases and lung injury. A state-of-the-art minireview. Chest 1983; 83: Suppl. 5, 54S-58S.
43. Janoff A. Elastase in tissue injury. Annu Rev Med 1985; 36: 207-216.
44. Okada Y, Watanabe S, Nakanishi I, et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 1988; 229: 157-160.
45. Döring G, Goldstein W, Botzenhart K, et al. Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol 1986; 597-605.
46. Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets 2008; 12: 145-157.
47. Lee WL, Downey GP. Leukocyte elastase: physiological functions and role in acute lung injury. Am J Respir Crit Care Med 2001; 164: 896-904.
48. Stockley RA. Proteases and antiproteases. Novartis Found Symp 2001; 234: 189-199.
49. Khan T, Wagener J, Bost T, Martinez J, Accurso F, Riches D. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
50. Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG. Elastolytic proteases. Inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005; 171: 1070-1076.
51. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86: 300-308.
52. Fick RB, Naegel GP, Squier SU, Wood RE, Gee JBL, Reynolds HY. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest 1984; 74: 236-248.
53. Griese M, Wiesener A, Lottspeich F, von Bredow C. Limited proteolysis of surfactant protein D causes a loss of its calcium-dependent lectin functions. Biochim Biophys Acta 2003; 1638: 157-163.
54. von Bredow C, Wiesener A, Griese M. Proteolysis of surfactant protein D by cystic fibrosis relevant proteases. Lung 2003; 181: 79-88.
55. Hirche TO, Crouch EC, Espinola M, et al. Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. J Biol Chem 2004; 279: 27688-27698.
56. Alcorn JF, Wright JR. Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol Chem 2004; 279: 30871-30879.
57. Lopez-boado YS, Espinola M, Bahr S, Belaaouaj A. Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity. J Immunol 2004; 172: 509-515.
58. Tsao F, Meyer K, Chen X, Rosenthal NS, Hu J. Degradation of annexin I in bronchoalveolar lavage fluid from patients with cystic fibrosis. Am J Respir Cell Mol Biol 1998; 18: 120-128.
59. Shamamian P, Schwartz JD, Pocock BJZ, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001; 189: 197-206.
60. Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol 2007; 9: 5871-5878.
61. Ferry G, Lonchampt M, Pennel L, deNanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-115.
62. Gaggar A, Li Y, Weathington N, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 2007; 293: L96-L104.
63. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002; 57: 930-934.
64. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-α and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-176.
65. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006; 12: 317-323.
66. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85: 682-689.
67. Fahy JV, Schuster A, Ueki I, Boushey HA, Nadel JA. Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases. Am Rev Respir Dis 1992; 146: 1430-1433.
68. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001; 108: 957-962.
69. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RAB, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000; 405: 85-90.
70. Vandivier RW, Fadok VA, Hoffmann PR, et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-670.
71. Huynh MLN, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50.
72. Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 upregulation by neutrophil elastase is mediated by MyD88/ IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001; 276: 35494-35499.
73. 4 by alveolar macrophages. J Clin Invest 1991; 88: 891-897.
74. Berger M, Sorensen RU, Tosi MF, Dearborn DG, Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989; 84: 1302-1313.
75. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor-necrosis-factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 1991; 266: 18846-18853.
76. Remold-O'Donnell E, Parent D. Specific sensitivity of CD43 to neutrophil elastase. Blood 1995; 86: 2395-2402.
77. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13: 1423-1430.
78. Döring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4 and CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995; 154: 4842-4850.
79. Nemoto E, Sugawara S, Tada H, Takada H, Shimauchi H, Horiuchi H. Cleavage of CD14 on human gingival fibroblasts cocultured with activated neutrophils is mediated by human leukocyte elastase resulting in down-regulation of lipopolysaccharide-induced IL-8 production. J Immunol 2000; 165: 5807-5813.
80. Le Barillec K, Si-Tahar M, Balloy V, Chignard M. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J Clin Invest 1999; 103: 1039-1046.
81. Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc 2002; 23: 19-25.
82. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992; 307: 97-101.
83. Hilliard JB, Konstan MW, Davis PB. Inflammatory mediators in CF patients. Methods Mol Med 2002; 70: 409-431.
84. Ratjen F, Rietschel E, Griese M, et al. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Eur Respir J 2000; 15: 141-145.
85. Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 2005; 40: 15-21.
86. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007; 4: 406-417.
87. Mussaffi H, Fireman EM, Mei-Zahav M, Prais D, Blau H. Induced sputum in the very young: a new key to infection and inflammation. Chest 2008; 133: 176-182.
88. Gutierrez JP, Grimwood K, Armstrong DS, et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001; 17: 281-286.
89. Balbi B, Pignatti P, Corradi M, et al. Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. Eur Respir J 2007; 30: 769-781.
90. Gibson PG, Grootendor DC, Henry RL, et al. Sputum induction in children. Eur Respir J 2002; 20: Suppl. 37, 44s-46s.
91. Mayer-Hamblett N, Aitken ML, Accurso FJ, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 822-828.
92. Armstrong DS, Grimwood K, Carzin R, Carlin B, Olinsky A. Lower airway inflammation in infants and young children with cystic fibrosis. BMJ 1995; 310: 1571-1572.
93. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005; 40: 500-510.
94. 1- Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-250.
95. Tiddens HA, de Jong PA. Update on the application of chest computed tomography scanning to cystic fibrosis. Curr Opin Pulm Med 2006; 12: 433-439.
96. Tiddens HA. Chest computed tomography scans should be considered as a routine investigation in cystic fibrosis. Paediatr Respir Rev 2006; 7: 202-208.
97. Reinhardt N, Chen CIU, Loppow D, et al. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Respir J 2003; 22: 497-502.
98. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
99. Rabin HR, Butler SM, Wohl MEB, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37: 400-406.
100. Jones A, Elphick H, Pettitt E, Everard ML, Evans GS. Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase. Eur Respir J 2002; 19: 1136-1141.
101. Campbell EJ, Senior RM, McDonald JA, Cox DL. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 1982; 70: 845-852.
102. Ohbayashi H. Current synthetic inhibitors of human neutrophil elastase in 2005. Expert Opin Ther Pat 2005; 15: 759-771.
103. Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995; 131: 775-789.
104. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999; 65: 137-150.
105. Owen CA. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 373-385.
106. Tremblay GM, Janelle MF, Bourbonnais Y. Anti-inflammatory activity of neutrophil elastase inhibitors. Curr Opin Investig Drugs 2003; 4: 556-565.
107. Attucci S, Gauthier A, Korkmaz B, et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther 2006; 318: 803-809.
108. Grimbert D, Vecellio L, Delepine P, et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 2003; 16: 121-129.
109. Delacourt C, Herigault S, Delclaux C, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir CellMol Biol 2002; 26: 290-297.
110. Birrer P, McElvaney NG, Gillissen A, et al. Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. J Appl Physiol 1992; 73: 317-323.
111. Tetley TD, Smith SF, Burton GH, Winning AJ, Cooke NT, Guz A. Effects of cigarette smoking and drugs on respiratory tract proteases and antiproteases. Eur J Respir Dis Suppl 1987; 153: 93-102.
112. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056-1060.
113. Sallenave JM, Marsden MD, Ryle AP. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. Biol Chem Hoppe Seyler 1992; 373: 27-33.
114. Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skinderived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 2000; 1: 87-92.
115. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/ elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994; 11: 733-741.
116. Maruyama M, Hay JG, Yoshimura K, Chu CS, Crystal RG. Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest 1994; 94: 368-375.
117. Taggart CC, Cryan SA, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659-1668.
118. Weldon S, McGarry N, Taggart CC, McElvaney NG. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. Biochem Soc Trans 2007; 35: 273-276.
119. Woods DE, Cantin A, Cooley J, Kenney DM, Remold-O'Donnell E. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 2005; 39: 141-149.
120. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001; 25: 492-499.
121. 1- Antitrypsin. J Med 1985; 16: 23-99.
122. Chughtai B, O'Riordan TG. Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med 2004; 17: 289-298.
123. Tebbutt SJ. Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL Therapeutics. Curr Opin Mol Ther 2000; 2: 199-204.
124. Cowden DI, Fisher GE, Weeks RL. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr Med Res Opin 2005; 21: 877-883.
125. Karnaukhova E, Ophir Y, Golding B. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids 2006; 30: 317-332.
126. 1-protease inhibitor for treatment of α-antitrypsin deficiency. Ann Pharmacother 2005; 39: 1861-1869.
127. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472.
128. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
129. Wewers MD, Casolaro MA, Crystal RG. Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy. Am Rev Respir Dis 1987; 135: 539-543.
130. McElvaney N, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. J Clin Invest 1992; 90: 1296-1301.
131. Wright G, Carver A, Cottom D, et al. High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y) 1991; 9: 830-834.
132. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168: Suppl., 565-578.
133. 1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 41: 177-183.
134. 1-antitrypsin. N Engl J Med 2005; 352: 2030-2031.
135. Vogelmeier C, Kirlath I, Warrington S, Banik N, Ulbrich E, Dubois RM. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155: 536-541.
136. 1-protease inhibitor) in CF. Paediatric Pulmonology 1995; 20: 421.
137. 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001; 22: 165-171.
138. 1-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulm Pharmacol Ther 2001; 14: 461-467.
139. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 29: 201-207.
140. Gibson R, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-951.